AngioDynamics, Inc. ANGO
AngioDynamics, Inc. (Nasdaq: ANGO) is a drug developer. Its lead program is marketed.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 2, 2026n/a Eric Honroth appointed President and Chief Executive Officer effective November 2, 2026.
On October 2, 2026, the Board of Directors of the Company appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026.
Filing - Oct 8, 2026n/a Howard W. Donnelly announces retirement as Class II director at end of current term.
On October 2, 2026, Howard W. Donnelly notified the Board of his intention to retire as a Class II director at the end of his current term.
Filing - Oct 8, 2026accepted FDA approved Investigational Device Exemption (IDE) for the RELIEF study evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia.
The Company received FDA approval of its IDE for the RELIEF study, a feasibility trial evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.